Provexis will develop the naturally derived casein, progress through clinical trials, and gain the necessary regulatory approvals. The partners will together identify the most appropriate commercialisation arrangements before the product is launched.
This marks a second collaboration for the two companies, after Provexis’ proprietary heart health technology Fruitflow was licensed to DSM in 2010. The acquisition will strengthen Provexis’ pipeline of innovative technologies for the functional and medical foods sectors.
This now includes a plantain-derived extract for the treatment of Crohn’s disease and work on an ingredient derived from cruciferous vegetables for cardiovascular inflammation. This latter research is being conducted in collaboration with the Institute of Food Research, Norwich, UK.
Stephen Moon, CEO at Provexis plc, said: “We are delighted to be entering into a development agreement with DSM on this new ingredient. From our experience with the development and commercialisation of Fruitflow, we know that there is a synergy between the two companies and that we can work together to create highly functional and profitable health and nutrition ingredients.”
Source: Provexis
© FoodBev Media Ltd 2024